![Roche Ireland on Twitter: "FoundationOne®CDx uses a sample of your cancer tissue and FoundationOne®Liquid CDx a blood sample to provide a more complete picture of your cancer and help open up treatment Roche Ireland on Twitter: "FoundationOne®CDx uses a sample of your cancer tissue and FoundationOne®Liquid CDx a blood sample to provide a more complete picture of your cancer and help open up treatment](https://pbs.twimg.com/media/FFsaWjGXMAINXxd.jpg)
Roche Ireland on Twitter: "FoundationOne®CDx uses a sample of your cancer tissue and FoundationOne®Liquid CDx a blood sample to provide a more complete picture of your cancer and help open up treatment
![Workflow for TMB assessment using the FoundationOne CDx assay [63].... | Download Scientific Diagram Workflow for TMB assessment using the FoundationOne CDx assay [63].... | Download Scientific Diagram](https://www.researchgate.net/publication/334081089/figure/fig2/AS:774610417090560@1561692923137/Workflow-for-TMB-assessment-using-the-FoundationOne-CDx-assay-63-ExAC-Exome.png)
Workflow for TMB assessment using the FoundationOne CDx assay [63].... | Download Scientific Diagram
![Comprehensive genomic profiling in oncology – from vision to reality | Latest news for Doctors, Nurses and Pharmacists | Pharmacy Comprehensive genomic profiling in oncology – from vision to reality | Latest news for Doctors, Nurses and Pharmacists | Pharmacy](https://pubmiddleware.mims.com/resource/image/838dc524-c270-4a4b-a623-a9de00fb1d90/OriginalThumbnail/THUMBNAIL_Genomic_Fig01.jpg)
Comprehensive genomic profiling in oncology – from vision to reality | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
![Pruebas genéticas de la línea germinal evalúan el riesgo heredado de cánceres mieloides - Hematología - mobile.Labmedica.es Pruebas genéticas de la línea germinal evalúan el riesgo heredado de cánceres mieloides - Hematología - mobile.Labmedica.es](https://globetechcdn.com/mobile_es_labmedica/images/stories/articles/article_images/2020-01-01/AyfNrjBQ.jpeg)
Pruebas genéticas de la línea germinal evalúan el riesgo heredado de cánceres mieloides - Hematología - mobile.Labmedica.es
![FoundationOne®CDx Receives FDA Approval as the First Companion Diagnostic to Identify Advanced Cancer Patients with Solid Tumors that are Tumor Mutational Burden-High (TMB-H) and Appropriate for Immunotherapy Treatment with KEYTRUDA® (pembrolizumab) FoundationOne®CDx Receives FDA Approval as the First Companion Diagnostic to Identify Advanced Cancer Patients with Solid Tumors that are Tumor Mutational Burden-High (TMB-H) and Appropriate for Immunotherapy Treatment with KEYTRUDA® (pembrolizumab)](https://mms.businesswire.com/media/20200617005328/en/627351/22/FMI_lockup%C2%AE_left_fire_RGB300ppi_For_BW.jpg)
FoundationOne®CDx Receives FDA Approval as the First Companion Diagnostic to Identify Advanced Cancer Patients with Solid Tumors that are Tumor Mutational Burden-High (TMB-H) and Appropriate for Immunotherapy Treatment with KEYTRUDA® (pembrolizumab)
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors | PLOS ONE
![FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire](https://mms.businesswire.com/media/20171130006320/en/627351/5/FMI_lockup%C2%AE_left_fire_RGB300ppi_For_BW.jpg)